{"id":"W2116385092","doi":"10.1200/jco.2007.13.0856","title":"Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Hospital","funders":"Eli Lilly Canada; American Society of Clinical Oncology; Merck KGaA; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gemcitabine; Carboplatin; Cetuximab; Lung cancer; Internal medicine; Chemotherapy; Clinical endpoint; Cisplatin; Pleural effusion; Phases of clinical research; Progression-free survival; Surgery; Gastroenterology; Oncology; Urology; Randomized controlled trial; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002723229,0.002296363,0.003592375,0.0005261307,0.0004884956,0.001421584,0.00134486,0.002103398,0.007355778],"category_scores_gemma":[0.0022104,0.001074654,0.001710434,0.0005487802,0.001633016,0.001278501,0.0005338931,0.004103608,0.001320634],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121884,"about_ca_system_score_gemma":0.002358766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041078,"about_ca_topic_score_gemma":0.003492808,"domain_scores_codex":[0.9990106,0.0006308607,0.00005346277,0.0001428871,0.00005413054,0.0001080611],"domain_scores_gemma":[0.9984066,0.0003746229,0.0003179875,0.0001180566,0.00009241167,0.0006903328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9706252,0.01275066,0.0005118143,0.0005055215,0.0007367747,0.00004020664,0.0000524365,0.0004177269,0.003376644,0.00009639224,0.0009405382,0.009946008],"study_design_scores_gemma":[0.9697374,0.02893342,0.0004093329,0.00001116022,0.0001556397,0.00001577625,0.000007341125,0.0001922713,0.0001985387,0.0000486819,0.0002851861,0.000005428287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9777034,0.004510561,0.001356495,0.001422926,0.001353478,0.009435487,0.001561868,0.0001818981,0.002473888],"genre_scores_gemma":[0.9751046,0.003432435,0.003073345,0.002309107,0.0007747502,0.00901763,0.001796251,0.00004753186,0.004444407],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007355778,"threshold_uncertainty_score":0.02460754,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07258268299772243,"score_gpt":0.5066041090782099,"score_spread":0.4340214260804874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}